ImmunoPrecise, NIH, Integrated Biotherapeutics test antibodies for COVID-19

By The Science Advisory Board staff writers

June 4, 2020 -- ImmunoPrecise Antibodies announced that it is collaborating with the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health (NIH) and Integrated Biotherapeutics to study molecular binding interactions of therapeutic antibody candidates for COVID-19.

The research consortium will characterize lead antibodies using cyrogenic electron microscopy (cryo-EM) to determine structural details of antibodies bound to the spike protein from SARS-CoV-2. Integrated Biotherapeutics will provide the trimeric spike protein ectodomain and receptor binding domain against which ImmunoPrecise's antibodies will be studied. The data will shed light on how ImmunoPrecise's lead candidate antibodies neutralize the virus.

Lilly begins COVID-19 antibody treatment clinical trials
Eli Lilly announced that the first patients have been dosed with its lead COVID-19 antibody treatment candidate, LY-CoV555, according to the firm. The...
AbCellera partners with Lilly for antibody discovery
AbCellera Biologics has joined forces with Eli Lilly on a multiyear initiative to identify antibodies for up to nine therapeutic targets.
Abcore develops antibodies against COVID-19
Antibody research and development firm Abcore said that it's discovered and tested a panel of functional therapeutic candidates for the treatment of COVID-19.
SARS-CoV mAb shown to block SARS-CoV-2
Antibodies from recovered SARS-CoV patients appear to block SARS-CoV-2 infectivity and could help in the development of antiviral treatments or vaccines,...
Yumab identifies COVID-19 antibody therapy
German biotechnology company Yumab said it has identified a promising candidate for COVID-19 antibody therapy.

Copyright © 2020

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter